Pfizer accelerates Crizotinib regulatory procedures
Pharmaceutical Business Review
Pfizer has received the US Food and Drug Adminstration's (FDA) acceptance for filing new drug application (NDA) for Crizotinib as a treatment for the patients who are suffering from ALK-positive advanced non-small cell lung cancer (NSCLC). …
Pfizer Lung Cancer Drug to Get Priority Review
FDA Grants Pfizer Priority Review For Lung Cancer Drug
Pfizer lung cancer drug – Is FDA becoming more Open to Experimental Therapies?
View full post on lung cancer – Google News